Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22765025 | 0.92 | PLAU (0.41) | PLAUPIM1PIM2MAPTPDE10A | |
| SCHEMBL1507889 | 0.90 | TP53 (0.40) | PLAUPIM1PIM2MAPTPDE10A | |
| SCHEMBL1507944 | 0.86 | PLAU (0.43) | PLAUPIM1PIM2MAPTPDE10A | |
| SCHEMBL7748081 | 0.81 | MAPT (0.57) | MAPTTP53THRBGAA | |
| SCHEMBL5959295 | 0.81 | PLAU (0.49) | PLAUMAPTRXFP1METAP1TP53 | |
| SCHEMBL30471577 | 0.81 | MAPT (0.57) | MAPTTP53THRBGAA | |
| SCHEMBL1507749 | 0.80 | TP53 (0.40) | PLAUPIM1PIM2MAPTPDE10A | |
| SCHEMBL14551175 | 0.78 | PLAU (0.46) | PLAUPIM1PIM2MAPTRXFP1 | |
| SCHEMBL22556188 | 0.77 | TDP1 (0.61) | MAPTMETAP1TP53GAA | |
| SCHEMBL22765141 | 0.77 | TDP1 (0.48) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | claimed |
| US-8324196-B2 | Polyquinoline derivatives and the therapeutic use thereof | PALUMED S.A. (FR) | 2012-12-04 | — | — | US | disclosed |
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-11-01 | — | — | US | disclosed |
| US-8247396-B2 | Polyquinoline derivatives and therapeutic use thereof | PALUMED S.A. (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-2289891-A2 | Novel polyquinoline derivates and the therapeutic use thereof | Palumed S.A. (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | HTT, APP, PSEN1 | PLAU 3064/4885PIM1 4677/4885PIM2 4674/4885 |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | HTT, UBQLN2, UBQLN1 | PLAU 3086/4885PIM1 4785/4885PIM2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.